open access

Vol 49, No 1 (2011)
Original paper
Published online: 2011-04-19
Submitted: 2011-12-19
Get Citation

Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia

Krzysztof Giannopoulos, Paulina Własiuk, Anna Dmoszyńska, Jacek Roliński, Michael Schmitt
DOI: 10.5603/FHC.2011.0023
·
Folia Histochem Cytobiol 2011;49(1):161-167.

open access

Vol 49, No 1 (2011)
ORIGINAL PAPERS
Published online: 2011-04-19
Submitted: 2011-12-19

Abstract

Although the immune status of chronic lymphocytic leukemia (CLL) patients is mostly characterized by immunosuppression, there is an accumulation of in vivo (graft-versus-leukemia effect) and in vitro (spontaneous remissions after infections) data that indicates that CLL might be effectively targeted by T-cell based immunotherapy. Recently, we characterized receptor for hyaluronic acid mediated motility (RHAMM) as a preferential target for immunotherapy of CLL. We also completed a RHAMM-derived peptide vaccination phase I/II clinical trial in CLL. Here, we present a detailed immunological analysis of six CLL patients vaccinated with HLA-A2 restricted RHAMM-derived epitope R3 (ILSLELMKL). Beside effective induction of R3-specific cytotoxic T-cells, peptide vaccination caused profound changes in different T-cell subsets as well as cytokines. We present longitudinal analyses of Th17, CD8+CD103+, CD8+CD137+ and IL-17 producing CD8+ T cells (CD8+IL- -17+) as well as important cytokines involved in regulation of immune response such as TGF-β, IL-10, IL-2 and TNF throughout the peptide vaccination period. (Folia Histochemica et Cytobiologica 2011, Vol. 49, No. 1, 161–167)

Abstract

Although the immune status of chronic lymphocytic leukemia (CLL) patients is mostly characterized by immunosuppression, there is an accumulation of in vivo (graft-versus-leukemia effect) and in vitro (spontaneous remissions after infections) data that indicates that CLL might be effectively targeted by T-cell based immunotherapy. Recently, we characterized receptor for hyaluronic acid mediated motility (RHAMM) as a preferential target for immunotherapy of CLL. We also completed a RHAMM-derived peptide vaccination phase I/II clinical trial in CLL. Here, we present a detailed immunological analysis of six CLL patients vaccinated with HLA-A2 restricted RHAMM-derived epitope R3 (ILSLELMKL). Beside effective induction of R3-specific cytotoxic T-cells, peptide vaccination caused profound changes in different T-cell subsets as well as cytokines. We present longitudinal analyses of Th17, CD8+CD103+, CD8+CD137+ and IL-17 producing CD8+ T cells (CD8+IL- -17+) as well as important cytokines involved in regulation of immune response such as TGF-β, IL-10, IL-2 and TNF throughout the peptide vaccination period. (Folia Histochemica et Cytobiologica 2011, Vol. 49, No. 1, 161–167)
Get Citation

Keywords

B-cell chronic lymphocytic leukemia (CLL); receptor for hyaluronic acid mediated motility (RHAMM); peptide immunotherapy

About this article
Title

Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 49, No 1 (2011)

Article type

Original paper

Pages

161-167

Published online

2011-04-19

DOI

10.5603/FHC.2011.0023

Bibliographic record

Folia Histochem Cytobiol 2011;49(1):161-167.

Keywords

B-cell chronic lymphocytic leukemia (CLL)
receptor for hyaluronic acid mediated motility (RHAMM)
peptide immunotherapy

Authors

Krzysztof Giannopoulos
Paulina Własiuk
Anna Dmoszyńska
Jacek Roliński
Michael Schmitt

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl